氯喹治疗洪都拉斯无并发症恶性疟原虫疟疾的疗效。
Efficacy of chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in Honduras.
机构信息
National Malaria Laboratory, National Department of Surveillance, Ministry of Health, Honduras.
出版信息
Am J Trop Med Hyg. 2013 May;88(5):850-4. doi: 10.4269/ajtmh.12-0671. Epub 2013 Mar 4.
Abstract
Chloroquine (CQ) is officially used for the primary treatment of Plasmodium falciparum malaria in Honduras. In this study, the therapeutic efficacy of CQ for the treatment of uncomplicated P. falciparum malaria in the municipality of Puerto Lempira, Gracias a Dios, Honduras was evaluated using the Pan American Health Organization-World Health Organization protocol with a follow-up of 28 days. Sixty-eight patients from 6 months to 60 years of age microscopically diagnosed with uncomplicated P. falciparum malaria were included in the final analysis. All patients who were treated with CQ (25 mg/kg over 3 days) cleared parasitemia by day 3 and acquired no new P. falciparum infection within 28 days of follow-up. All the parasite samples sequenced for CQ resistance mutations (pfcrt) showed only the CQ-sensitive genotype (CVMNK). This finding shows that CQ remains highly efficacious for the treatment of uncomplicated P. falciparum malaria in Gracias a Dios, Honduras.
摘要
氯喹（CQ）在洪都拉斯被正式用于治疗恶性疟原虫疟疾。在这项研究中，采用泛美卫生组织-世界卫生组织方案，对洪都拉斯格拉西亚斯-阿迪奥斯市波多黎各伦皮拉区的单纯性恶性疟原虫疟疾的 CQ 治疗疗效进行了评估，随访 28 天。最终分析中包括 68 名年龄在 6 个月至 60 岁之间经显微镜诊断为单纯性恶性疟原虫疟疾的患者。所有接受 CQ（3 天 25mg/kg）治疗的患者在第 3 天清除了寄生虫血症，在随访的 28 天内没有发生新的恶性疟原虫感染。对 CQ 耐药突变（pfcrt）进行测序的所有寄生虫样本均显示只有 CQ 敏感基因型（CVMNK）。这一发现表明，CQ 对洪都拉斯格拉西亚斯-阿迪奥斯市的单纯性恶性疟原虫疟疾的治疗仍然非常有效。
相似文献
1
Efficacy of chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in Honduras.氯喹治疗洪都拉斯无并发症恶性疟原虫疟疾的疗效。
Am J Trop Med Hyg. 2013 May;88(5):850-4. doi: 10.4269/ajtmh.12-0671. Epub 2013 Mar 4.
2
Efficacy of chloroquine plus primaquine treatment and pfcrt mutation in uncomplicated falciparum malaria patients in Rangamati, Bangladesh.氯喹加伯氨喹治疗以及 pfcrt 突变在孟加拉国朗加马蒂单纯性恶性疟患者中的疗效
Parasitol Int. 2011 Dec;60(4):341-6. doi: 10.1016/j.parint.2011.05.007. Epub 2011 May 30.
3
Therapeutic efficacy of chloroquine and sequence variation in pfcrt gene among patients with falciparum malaria in central India.印度中部地区间日疟原虫感染患者应用氯喹的疗效与 pfcrtt 基因序列变异的关系
Trop Med Int Health. 2010 Jan;15(1):33-40. doi: 10.1111/j.1365-3156.2009.02425.x. Epub 2009 Nov 11.
4
Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum.在接受氯喹治疗的感染恶性疟原虫的苏丹患者中，pfcrt 等位基因 CVMNK 和 CVIET 的动态变化。
Malar J. 2010 Mar 12;9:74. doi: 10.1186/1475-2875-9-74.
5
High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy.在也门恶性疟原虫氯喹耐药标记（pfcrt T76 突变）高频出现：急需重新审查疟疾药物政策。
Parasit Vectors. 2011 May 27;4:94. doi: 10.1186/1756-3305-4-94.
6
Rapid detection of Pfcrt and Pfmdr1 mutations in Plasmodium falciparum isolates by FRET and in vivo response to chloroquine among children from Osogbo, Nigeria.通过荧光共振能量转移（FRET）快速检测尼日利亚奥索博儿童恶性疟原虫分离株中的Pfcrt和Pfmdr1突变以及对氯喹的体内反应。
Malar J. 2007 Apr 11;6:41. doi: 10.1186/1475-2875-6-41.
7
Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.瓦努阿图共和国的活动性病例检测、采用氯喹和磺胺多辛/乙胺嘧啶联合治疗恶性疟和氯喹治疗间日疟以及抗疟药物耐药性的分子标记物。
Malar J. 2010 Apr 6;9:89. doi: 10.1186/1475-2875-9-89.
8
Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria.尼日利亚疟疾患者中恶性疟原虫pfcrt和pfmdr - 1基因的点突变及对氯喹的临床反应
Ann Trop Med Parasitol. 2003 Jul;97(5):439-51. doi: 10.1179/000349803235002489.
9
Plasmodium falciparum gametocytaemia in Nigerian children: Peripheral immature gametocytaemia as an indicator of a poor response to chloroquine treatment, and its relationship to molecular determinants of chloroquine resistance.尼日利亚儿童中的恶性疟原虫配子体血症：外周血未成熟配子体血症作为氯喹治疗反应不佳的指标及其与氯喹抗性分子决定因素的关系
Ann Trop Med Parasitol. 2003 Jul;97(5):453-68. doi: 10.1179/000349803235002443.
10
Polymorphisms in Pfcrt and Pfmdr-1 genes after five years withdrawal of chloroquine for the treatment of Plasmodium falciparum malaria in West Bengal, India.在印度西孟加拉邦停止使用氯喹治疗恶性疟原虫疟疾五年后，Pfcrt和Pfmdr-1基因的多态性
Infect Genet Evol. 2016 Oct;44:281-285. doi: 10.1016/j.meegid.2016.07.021. Epub 2016 Jul 20.
引用本文的文献
1
Genetic diversity of and field isolates from Honduras in the malaria elimination phase.洪都拉斯处于疟疾消除阶段的[具体疟原虫种类]和现场分离株的遗传多样性。 （注：原文中“and”前缺少具体疟原虫种类等关键信息，导致翻译不是特别完整准确，仅按现有原文结构翻译）
Curr Res Parasitol Vector Borne Dis. 2024 Nov 21;7:100230. doi: 10.1016/j.crpvbd.2024.100230. eCollection 2025.
2
Geo-classification of drug-resistant travel-associated using and gene sequences (USA, 2018-2021).利用[具体内容]和基因序列对耐多药旅行相关[具体内容]进行地理分类（美国，2018 - 2021年） 。
你提供的原文似乎有部分内容缺失，翻译可能会不太准确完整，你可以补充完整后再让我翻译。
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0120324. doi: 10.1128/aac.01203-24. Epub 2024 Nov 12.
3
Chloroquine: A Potential Drug in the COVID-19 Scenario.氯喹：COVID-19情况下的一种潜在药物。
Trans Indian Natl Acad Eng. 2020;5(2):399-410. doi: 10.1007/s41403-020-00114-w. Epub 2020 Jun 7.
4
Bitter taste receptors in the reproductive system: Function and therapeutic implications.生殖系统中的苦味受体：功能与治疗意义。
J Cell Physiol. 2024 Feb;239(2):e31179. doi: 10.1002/jcp.31179. Epub 2024 Jan 14.
5
Drug resistance and population structure of Plasmodium falciparum and Plasmodium vivax in the Peruvian Amazon.秘鲁亚马逊地区疟原虫和间日疟原虫的耐药性和种群结构。
Sci Rep. 2022 Oct 1;12(1):16474. doi: 10.1038/s41598-022-21028-3.
6
Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya.在肯尼亚西部 Asembo，人类血液中疟原虫耐药分子标志物的时间趋势及蚊卵中相应耐药标志物的特征。
Malar J. 2022 Sep 13;21(1):265. doi: 10.1186/s12936-022-04284-6.
7
Co-administration of chloroquine and coenzyme Q improved treatment outcome during experimental cerebral malaria.在实验性脑型疟疾期间，氯喹与辅酶Q联合使用改善了治疗效果。
J Parasit Dis. 2022 Jun;46(2):466-475. doi: 10.1007/s12639-022-01468-4. Epub 2022 Jan 31.
8
Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfcrt and pfmdr1 genes in isolates from Honduras and Nicaragua, 2018-2021.评估 2018-2021 年洪都拉斯和尼加拉瓜分离株中 pfcrt 和 pfmdr1 基因的恶性疟原虫抗疟药耐药标志物。
Malar J. 2021 Dec 14;20(1):465. doi: 10.1186/s12936-021-03977-8.
9
Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence.孕期使用氯喹和羟氯喹以及基于真实世界证据的不良妊娠结局风险
Front Pharmacol. 2021 Aug 2;12:722511. doi: 10.3389/fphar.2021.722511. eCollection 2021.
10
Cross-resistance of the chloroquine-derivative AQ-13 with amodiaquine in Cambodian Plasmodium falciparum isolates.氯喹衍生物 AQ-13 与阿莫地喹在柬埔寨疟原虫分离株中的交叉耐药性。
J Antimicrob Chemother. 2021 Sep 15;76(10):2565-2568. doi: 10.1093/jac/dkab219.
本文引用的文献
1
Lack of evidence for chloroquine-resistant Plasmodium falciparum malaria, Leogane, Haiti.海地莱奥甘缺乏耐氯喹恶性疟原虫疟疾的证据。
Emerg Infect Dis. 2012 Sep;18(9):1487-9. doi: 10.3201/eid1809.120605.
2
Comparison of molecular tests for the diagnosis of malaria in Honduras.洪都拉斯疟疾诊断的分子检测比较。
Malar J. 2012 Apr 18;11:119. doi: 10.1186/1475-2875-11-119.
3
Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.中美洲洪都拉斯采集的疟原虫恶性疟原虫和间日疟原虫相关耐药基因突变。
Malar J. 2011 Dec 19;10:376. doi: 10.1186/1475-2875-10-376.
4
Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar.在马达加斯加，恶性疟原虫氯喹临床治疗失败与 Pfmdr-1 基因突变有关，而不是 Pfcrt。
PLoS One. 2010 Oct 13;5(10):e13281. doi: 10.1371/journal.pone.0013281.
5
High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India.印度卡尼科巴岛的恶性疟原虫患者中氯喹治疗失败率高且突变基因型为主，与氯喹和抗叶酸耐药有关。
J Antimicrob Chemother. 2010 Jun;65(6):1258-61. doi: 10.1093/jac/dkq090. Epub 2010 Apr 2.
6
pfmdr1 amplification and fixation of pfcrt chloroquine resistance alleles in Plasmodium falciparum in Venezuela.委内瑞拉恶性疟原虫 pfmdr1 扩增与 pfcrt 氯喹耐药等位基因固定。
Antimicrob Agents Chemother. 2010 Apr;54(4):1572-9. doi: 10.1128/AAC.01243-09. Epub 2010 Feb 9.
7
Recognition, perceptions and treatment practices for severe malaria in rural Tanzania: implications for accessing rectal artesunate as a pre-referral.坦桑尼亚农村地区对重症疟疾的认识、看法和治疗做法：对获得直肠青蒿琥酯作为转诊前治疗的影响。
PLoS One. 2007 Jan 17;2(1):e149. doi: 10.1371/journal.pone.0000149.
8
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.乌干达抗疟药物疗效的地理差异是由疟疾流行程度的差异而非已知的耐药分子标记所解释的。
J Infect Dis. 2006 Apr 1;193(7):978-86. doi: 10.1086/500951. Epub 2006 Mar 1.
9
10
Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum.恶性疟原虫所致疟疾患儿的奎宁药代动力学与药效学
Antimicrob Agents Chemother. 2005 Sep;49(9):3658-62. doi: 10.1128/AAC.49.9.3658-3662.2005.
Zotero 插件